J A Erhardt

Summary

Affiliation: SmithKline Beecham Pharmaceuticals
Country: USA

Publications

  1. ncbi request reprint Activation of caspase-3/caspase-3-like activity in rat cardiomyocytes by an RGD peptide, but not the GPIIb/IIIa antagonist lotrafiban
    J A Erhardt
    Department of Cardiovascular Pharmacology, GlaxoSmithKline, King of Prussia, PA 19406, USA
    Thromb Res 103:143-8. 2001
  2. ncbi request reprint Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia
    F C Barone
    SmithKline Beecham Pharmaceuticals, Department of Cardiovascular Pharmacology, King of Prussia, PA 19406, USA
    Med Res Rev 21:129-45. 2001
  3. ncbi request reprint SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia
    F C Barone
    Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA
    J Pharmacol Exp Ther 296:312-21. 2001
  4. ncbi request reprint SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia
    J J Legos
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, PO Box 1539, 709 Swedeland Road, King of Prussia, PA 19406, USA
    Brain Res 892:70-7. 2001
  5. ncbi request reprint Small proteins that modulate calmodulin-dependent signal transduction: effects of PEP-19, neuromodulin, and neurogranin on enzyme activation and cellular homeostasis
    J R Slemmon
    Department of Protein Biochemistry, SmithKline Beecham Pharmaceuticals Research and Development, King of Prussia, PA 19406, USA
    Mol Neurobiol 22:99-113. 2000
  6. ncbi request reprint P2X1 stimulation promotes thrombin receptor-mediated platelet aggregation
    J A Erhardt
    GlaxoSmithKline, Department of Vascular Biology, King of Prussia, PA 19406, USA
    J Thromb Haemost 4:882-90. 2006
  7. ncbi request reprint A comparison of the beta-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis
    J R Toomey
    Cardiovascular and Urogenital Diseases Center of Excellence, GlaxoSmithKline, King of Prussia, PA, USA
    J Thromb Haemost 4:1989-96. 2006

Detail Information

Publications7

  1. ncbi request reprint Activation of caspase-3/caspase-3-like activity in rat cardiomyocytes by an RGD peptide, but not the GPIIb/IIIa antagonist lotrafiban
    J A Erhardt
    Department of Cardiovascular Pharmacology, GlaxoSmithKline, King of Prussia, PA 19406, USA
    Thromb Res 103:143-8. 2001
  2. ncbi request reprint Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia
    F C Barone
    SmithKline Beecham Pharmaceuticals, Department of Cardiovascular Pharmacology, King of Prussia, PA 19406, USA
    Med Res Rev 21:129-45. 2001
    ....
  3. ncbi request reprint SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia
    F C Barone
    Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA
    J Pharmacol Exp Ther 296:312-21. 2001
    ....
  4. ncbi request reprint SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia
    J J Legos
    Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, PO Box 1539, 709 Swedeland Road, King of Prussia, PA 19406, USA
    Brain Res 892:70-7. 2001
    ....
  5. ncbi request reprint Small proteins that modulate calmodulin-dependent signal transduction: effects of PEP-19, neuromodulin, and neurogranin on enzyme activation and cellular homeostasis
    J R Slemmon
    Department of Protein Biochemistry, SmithKline Beecham Pharmaceuticals Research and Development, King of Prussia, PA 19406, USA
    Mol Neurobiol 22:99-113. 2000
    ..Data from studies on neuromodulin, neurogranin, and PEP-19 suggest that they play an important role in establishing some of the processes by which this regulation is accomplished...
  6. ncbi request reprint P2X1 stimulation promotes thrombin receptor-mediated platelet aggregation
    J A Erhardt
    GlaxoSmithKline, Department of Vascular Biology, King of Prussia, PA 19406, USA
    J Thromb Haemost 4:882-90. 2006
    ..Overall, the present study defines a novel interaction between platelet P2X1 and thrombin receptors, with P2X1 functioning to amplify aggregation responses at low levels of thrombin receptor stimulation...
  7. ncbi request reprint A comparison of the beta-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis
    J R Toomey
    Cardiovascular and Urogenital Diseases Center of Excellence, GlaxoSmithKline, King of Prussia, PA, USA
    J Thromb Haemost 4:1989-96. 2006
    ..Additionally, studies were conducted to investigate odiparcil's ex vivo antithrombin and antiplatelet activity, and also to explore the potential utility of protamine sulfate as a neutralizing agent...